The Latest Breaking News from Alzheimer Disease

As the population ages, the number of people with neurodegenerative diseases, such as Alzheimer’s disease, increases. Approximately 75,000 Canadians are diagnosed with Alzheimer’s disease each year and experience a decline in their cognitive abilities. The ordeal usually lasts for several years while their family members watch helplessly.

A new study found a link between higher concentrations of Vitamin D and improved cognition in aging people.

Hunter residents at high risk of developing Alzheimer's Disease will be given access to a clinical trial involving a breakthrough drug that appears to slow the development of the disease.

Lecanemab has been shown in trials to slow the progress of early-stage Alzheimer's by 27%

As trial results bring hope of an effective treatment, Lisa Salmon asks The Alzheimer’s Society what it means for people right now.

Lecanemab, a newly developed drug, has showed promising results in clinical trials among Alzheimer patients

Data supports claims that a new drug reduced cognitive and functional decline in Alzheimer's patients by 27 per cent in a clinical trial.

The drug slowed the disease progression by 27 percent compared to patients taking the placebo.

Lecanemab was found to have reduced memory decline by targeting and clearing amyloid, which is one of the proteins that build up in the brains of people with the disease